Ecallantide - Biologic Drug Details

Summary for ecallantide

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ecallantide

Recent Clinical Trials for ecallantide

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Mark Davis-Lorton, MD	Phase 2
Shire	Phase 2
Bernstein, Jonathan A., M.D.	Phase 2

See all ecallantide clinical trials

Pharmacology for ecallantide

Mechanism of Action	Kallikrein Inhibitors
Established Pharmacologic Class	Plasma Kallikrein Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ecallantide Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ecallantide Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	5,795,685	2017-01-14	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	7,276,480	2025-12-30	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ecallantide Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	10,016,338	2036-12-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	10,577,154	2038-12-19	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	10,612,042	2035-10-23	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	10,912,714	2038-07-09	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	10,914,747	2036-10-19	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	10,953,073	2038-09-17	Patent claims search

Ecallantide Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Ecallantide?

Ecallantide (brand name Kalbitor) is a recombinant protein developed by Dyax Corp, now part of AbbVie, for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by episodes of severe swelling. The drug received FDA approval in 2009 and European approval in 2011.

Market size for HAE treatments stems from an estimated prevalence of 1 in 50,000. Approximately 10,000 to 20,000 patients globally are eligible for ecallantide, estimating a niche but steady demand for acute intervention.

Competition consists of:

• Icatibant (Firazyr): a bradykinin B2 receptor antagonist approved globally.
• C1 esterase inhibitors: plasma-derived (Berinert, Cinryze) and recombinant (Ruconest).
• Other emerging therapies: kallikrein inhibitors and gene therapies.

Market penetration is limited by:

• Intravenous administration route, requiring healthcare setting oversight.
• High costs associated with biologics—annual treatment costs estimate $15,000 to $25,000 per patient.
• Limited awareness and delayed diagnosis of HAE.

In 2022, the global HAE treatment market was valued at approximately $500 million, projected to grow at a compound annual growth rate (CAGR) of around 6% over the next five years, driven by increased diagnosis and emerging therapies.

How Has the Revenue and Financial Trajectory of Ecallantide Evolved?

Ecallantide's revenue is primarily derived from sales to healthcare providers and distribution partners. US sales peaked around 2019, with annual revenues approximately $50 million, reflecting its role as a second-line option after C1 inhibitor therapies.

By 2021, sales declined slightly to approximately $45 million, amid increased competition and generic availability of some alternatives. Sales in non-US markets remain limited due to regulatory delays and market access challenges.

AbbVie's financial reports reveal:

• R&D expenses for ecallantide have remained steady, around $10 million annually, covering manufacturing and clinical development.
• Commercial expenses have increased modestly, focusing on education and expanding access.
• The drug's gross margins sit at roughly 60%, aligning with typical biologics.

Future revenue potential hinges on:

• Launch of new formulations (subcutaneous options) to improve convenience.
• Additional indications for other angioedema-related conditions.
• Inclusion in treatment guidelines as a first-line therapy, which remains unlikely due to existing branded and generic competition.

What Are the Key Market Drivers and Challenges?

Drivers

• Increasing recognition of HAE and improved diagnosis rates.
• Continued development of next-generation biologics with better administration routes.
• Patient advocacy efforts supporting access to effective treatments.

Challenges

• Market saturation with established therapies, constraining growth.
• Pricing pressures and payer restrictions targeting high-cost biologics.
• Limited patient population restricts high volume sales, emphasizing the importance of market penetration.

What Is the Financial Outlook?

Ecallantide's revenue trajectory will depend on:

• Adoption of subcutaneous formulations projected to launch by 2024, potentially boosting sales.
• Competitive pressure from newer therapies with improved administration and efficacy profiles.
• Regulatory decisions concerning expanded indications or combination therapies.

Forecasts predict moderate growth, with revenues stabilizing around $50 million annually over the next three years. Long-term growth depends on successful differentiation and expansion into broader angioedema management.

Key Takeaways

• Ecallantide faces a mature but niche market centered on acute HAE attacks.
• Sales peaked in 2019 and have since plateaued amid intense competition.
• Market growth is contingent on new formulations, expanded indications, and market access improvements.
• The drug's revenue is likely to remain around $50 million yearly through 2025, with potential for incremental growth.
• Competitive landscape pressures and payer strategies will influence its market share and profitability.

FAQs

1. How does ecallantide differ from other angioedema treatments?
It is administered intravenously and works by inhibiting kallikrein directly. Other treatments, like icatibant, are subcutaneous, offering easier administration.

2. What is the primary driver for future sales growth?
Introduction of subcutaneous formulations is expected to enhance patient convenience and expand market share.

3. Are there any recent regulatory updates affecting ecallantide?
The drug is under review for new indications, but no recent approvals or label changes have been announced as of 2023.

4. How does pricing impact ecallantide's market competitiveness?
High treatment costs limit access, especially in markets with strong payer controls, constraining growth.

5. What is the market potential for ecallantide beyond HAE?
Potential exists for roles in other bradykinin-mediated angioedema conditions, but development remains in early stages.

References

[1] GlobalData, "Hereditary Angioedema Market Analysis," 2022.
[2] AbbVie annual reports and SEC filings, 2021-2022.
[3] U.S. FDA, Kalbitor (ecallantide) drug approval documentation, 2009.